Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jin, Nana ^a   Wu, Hao ^a   Miao, Zhengqiang ^a   Huang, Yan ^a   Hu, Yongfei ^a   Bi, Xiaoman ^a   Wu, Deng ^a   Qian, Kun ^a   Wang, Liqiang ^a   Wang, Changliang ^a   Wang, Hongwei ^a   Li, Kongning ^a   Li, Xia ^a   Wang, Dong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER GRADING; CELL DEATH; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; CELL DEATH; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84934915971     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11566     Document Type: Article

References (63)

1. Siegel, R. L., Miller, K. D., Jemal, A. Cancer statistics, 2015. CA. Cancer J. Clin. 65, 5-29; doi: 10.3322/caac.21254 (2015).
2. Slomski, A. Screening women for ovarian cancer still does more harm than good. JAMA 307, 2474-2475; doi: 10.1001/jama.2012.5646 (2012).
3. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615; doi: 10.1038/nature10166 (2011).
4. Bast, R. C., Jr., Hennessy, B., Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9, 415-428; doi: 10.1038/nrc2644 (2009).
5. Risch, H. A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98, 1694-1706; doi: 10.1093/jnci/djj465 (2006).
6. Pal, T. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104, 2807-2816; doi: 10.1002/cncr.21536 (2005).
7. Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49-56; doi: 10.1002/path.2696 (2010).
8. Cantor, J. R., Sabatini, D. M. Cancer cell metabolism: one hallmark, many faces. Cancer discov. 2, 881-898; doi: 10.1158/2159-8290.CD-12-0345 (2012).
9. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674; doi: 10.1016/j.cell.2011.02.013 (2011).
10. Barabasi, A. L., Gulbahce, N., Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68; doi: 10.1038/nrg2918 (2011).
11. Taylor, I. W. et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204; doi: 10.1038/nbt.1522 (2009).
12. Hofree, M., Shen, J. P., Carter, H., Gross, A., Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108-1115; doi: 10.1038/nmeth.2651 (2013).
13. Ideker, T., Krogan, N. J. Differential network biology. Mol. Syst. Biol. 8, 565; doi: 10.1038/msb.2011.99 (2012).
14. Bonnefond, M. L. et al. Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation. Apoptosis 20, 535-550; doi: 10.1007/s10495-015-1095-3 (2015).
15. Chandler, R. L. et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat. Commun. 6, 6118; doi: 10.1038/ncomms7118 (2015).
16. Li, L. et al. MiR-17-5p Up-Regulates YES1 to Modulate the Cell Cycle Progression and Apoptosis in Ovarian Cancer Cell Lines. J. Cell. Biochem. 116, 1050-1059; doi: 10.1002/jcb.25060 (2015).
17. Knutson, K. L., Karyampudi, L., Lamichhane, P., Preston, C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 34, 53-74; doi: 10.1007/s10555-014-9540-2 (2015).
18. Jacobson, M. D., Weil, M., Raff, M. C. Programmed cell death in animal development. Cell 88, 347-354 (1997).
19. Denoyelle, C. et al. miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell death dis. 5, e1445; doi: 10.1038/cddis.2014.389 (2014).
20. Simonin, K. et al. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 18, 492-508; doi: 10.1007/s10495-012-0799-x (2013).
21. Mathew, R. et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062-1075; doi: 10.1016/j. cell.2009.03.048 (2009).
22. Oliveira-Ferrer, L. et al. c-FOS suppresses ovarian cancer progression by changing adhesion. Br. J. Cancer 110, 753-763; doi: 10.1038/bjc.2013.774 (2014).
23. Wang, H. et al. Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour Biol. 34, 3101-3109; doi: 10.1007/s13277-013-0878-9 (2013).
24. Cao, J. et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol. Rep. 30, 701-706; doi: 10.3892/or.2013.2482 (2013).
25. Hafezi, F. et al. The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. Nat. Med. 3, 346-349 (1997).
26. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815; doi: 10.1093/nar/gks1094 (2013).
27. Li, Y. et al. Connect the dots: a systems level approach for analyzing the miRNA-mediated cell death network. Autophagy 9, 436-439; doi: 10.4161/auto.23096 (2013).
28. Xu, J., Li, Y. H. miRDeathDB: a database bridging microRNAs and the programmed cell death. Cell Death Differ. 19, 1571; doi: 10.1038/cdd.2012.87 (2012).
29. Moussay, E. et al. The acquisition of resistance to TNFalpha in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. Autophagy 7, 760-770; doi: 10.4161/auto.7.7.15454 (2011).
30. Diez, J., Walter, D., Munoz-Pinedo, C., Gabaldon, T. DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death. Cell Death Differ. 17, 735-736; doi: 10.1038/cdd.2009.215 (2010).
31. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504; doi: 10.1101/gr.1239303 (2003).
32. Jiang, L. et al. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol. cancer 9, 318; doi: 10.1186/1476-4598-9-318 (2010).
33. Woenckhaus, J. et al. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 450, 387-395; doi: 10.1007/s00428-006-0358-3 (2007).
34. Aya Sultan, C. Y. W., George E., Duran, E., Brian Francisco, Jonathan S., Berek & Branimir, I. Sikic. Abstract 1401: SYK promotes tumor progression in ovarian cancer cell lines. Cancer Res. 71, 1401; doi: 10.1158/1538-7445. (2011).
35. Yoshihara, K. et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res. 18, 1374-1385; doi: 10.1158/1078-0432.CCR-11-2725 (2012).
36. Huang da, W., Sherman, B. T., Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57; doi: 10.1038/nprot.2008.211 (2009).
37. Dennis, G., Jr. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, P3; doi: 10.1186/gb-2003-4-5-p3 (2003).
38. Heck, E. et al. T-cell growth transformation by herpesvirus saimiri is independent of STAT3 activation. J. Virol. 79, 5713-5720; doi: 10.1128/JVI.79.9.5713-5720.2005 (2005).
39. Kurita, T. et al. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 103, 239-444; doi: 10.1111/j.1349-7006.2011.02156.x (2012).
40. Sorrentino, A. et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111, 478-486; doi: 10.1016/j. ygyno.2008.08.017 (2008).
41. Li, J., Roebuck, P., Grunewald, S., Liang, H. SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data. Nucleic Acids Res. 40, W123-W126; doi: 10.1093/nar/gks386 (2012).
42. Segura, M. F. et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin. Cancer Res. 16, 1577-1586; doi: 10.1158/1078-0432.CCR-09-2721 (2010).
43. Wang, D. et al. Evaluation of cDNA microarray data by multiple clones mapping to the same transcript. OMICS 13, 493-499; doi: 10.1089/omi.2009.0077 (2009).
44. Bonome, T. et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68, 5478-5486; doi: 10.1158/0008-5472.CAN-07-6595 (2008).
45. Zhang, X. et al. RAID: a comprehensive resource for human RNA-associated (RNA-RNA/RNA-protein) interaction. RNA 20, 989-993; doi: 10.1261/rna.044776.114 (2014).
46. Hsu, S. D. et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 42, D78-D85; doi: 10.1093/nar/gkt1266gkt1266 (2014).
47. Ideker, T., Ozier, O., Schwikowski, B., Siegel, A. F. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 18 Suppl 1, S233-S240 (2002).
48. Kirkpatrick, S., Gelatt, C. D., Jr., Vecchi, M. P. Optimization by simulated annealing. Science 220, 671-680; doi: 10.1126/science.220.4598.671 (1983).
49. Kim, Y. et al. Principal network analysis: identification of subnetworks representing major dynamics using gene expression data. Bioinformatics 27, 391-398; doi: 10.1093/bioinformatics/btq670 (2011).
50. Nepusz, T., Yu, H., Paccanaro, A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat. Methods 9, 471-472; doi: 10.1038/nmeth.1938 (2012).
51. Bader, G. D., Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4, 2; doi: 10.1186/1471-2105-4-2 (2003).
52. Liu, W., Li, L., Li, W. Gene co-expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines. Int. J. Cancer 135, 2795-2803; doi: 10.1002/ijc.28935 (2014).
53. Das, H. et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br. J. Cancer 82, 1682-1688; doi: 10.1054/bjoc.2000.1118 (2000).
54. Hein, S. et al. Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol. Rep. 22, 177-183; doi: 10.3892/or-00000422 (2009).
55. Ravikumar, S., Perez-Liz, G., Del Vale, L., Soprano, D. R., Soprano, K. J. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid. Cancer Res. 67, 9266-9275; doi: 10.1158/0008-5472.CAN-07-2088 (2007).
56. Fan, Y. et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 30, 241-245; doi: 10.1089/dna.2010.1107 (2011).
57. Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681; doi: 10.1158/0008-5472.CAN-04-2933 (2004).
58. Zhang, L. et al. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin. Cancer Res. 13, 5314-5321; doi: 10.1158/1078-0432.CCR-06-2660 (2007).
59. Niesporek, S. et al. [NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]. Verh. Dtsch. Ges. Pathol. 91, 243-249 (2007).
60. Wiener, J. R. et al. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin. Cancer Res. 5, 2164-2170 (1999).
61. Gest, C. et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett. 317, 207-217; doi: 10.1016/j. canlet.2011.11.026 (2012).
62. McCann, G. A. et al. Targeting constitutively-activated STAT3 in hypoxic using a novel STAT3 inhibitor. Oncoscience 1, 216-228 (2014)
63. Miles, G. D., Seiler, M., Rodriguez, L., Rajagopal, G., Bhanot, G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res. Notes 5, 164; doi: 10.1186/1756-0500-5-164 (2012).